Irinotecan Dosage Adjustment for Colon Cancer and Hepatic Dysfunction

Purpose: To adjust the recommended dose of irinotecan for a patient with colon cancer based on the level of hepatic dysfunction as reported by Raymond et al.

Info MyLikes MyPaths

Evaluation

Are you evaluating a patient with colon cancer?

Yes

Body weigh

Body height

Serum total bilirubin

Upper limit of normal for serum total bilirubin

Results

Please fill out required fields.

Results Interpretation and Description References Next Steps

Data complete?

Evaluation appropriate?

Body surface area

Ratio of serum total bilirubin to its upper limit of normal

Recommended dose for irinotecan

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Seamlessly integrate our API library of over 5,000 evidence-based medical analytics into your products and workflows. Our APIs help you:

Build custom, automated clinical workflows tailored to your organization's needs.
Enhance your clinical decision support with advanced, evidence-based analytics.
Streamline revenue cycle management by integrating clinical analytics into billing, coding, and compliance processes.
Support payment and pre-approval processes with automated, standardized medical criteria.
Embed proven medical algorithms directly into your systems and services for consistent, high-quality outcomes.

With MedicalAlgorithms.com APIs, you can accelerate innovation, improve efficiency, and deliver more accurate, data-driven care—without reinventing the wheel.

Explore Medal API

Caution: A qualified health practitioner should verify all results.
Keep patient data confidential and comply with all legal requirements.

Please visit our website Medicalalgorithms.com for Description and Interpretation and further algorithms you may want to consider in the next steps of your evaluation. All information should be verified by a qualified health professional, and all use is subject to Medicalalgorithms.com Terms and Conditions. © Copyright Medicalalgorithms.com Limited

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Risk Factors
- Pharmacokinetic Test Dose to Detect Risk for Excessive Toxicity Prior to 5-Fluorouracil Therapy
Criteria For Diagnosis
- World Health Organization (WHO) Criteria for Tumor Response to Therapy
Severity, Prognosis, Stage
- World Health Organization (WHO) Criteria for Tumor Response to Therapy

Therapy

Options
- World Health Organization (WHO) Criteria for Tumor Response to Therapy
Selection
- World Health Organization (WHO) Criteria for Tumor Response to Therapy
- Pharmacokinetic Test Dose to Detect Risk for Excessive Toxicity Prior to 5-Fluorouracil Therapy

Monitoring

Response To Therapy
Disease Progression
- World Health Organization (WHO) Criteria for Tumor Response to Therapy

Specialty

Hematology Oncology
Surgery, general

Objective

dosage adjustments

ICD-10

C18 - Malignant neoplasm of colon
C19 - Malignant neoplasm of rectosigmoid junction
C20 - Malignant neoplasm of rectum
K76.8 - Other specified diseases of liver

Info

Purpose: To adjust the recommended dose of irinotecan for a patient with colon cancer based on the level of hepatic dysfunction as reported by Raymond et al.

Specialty: Hematology Oncology, Surgery, general

Objective: dosage adjustments

ICD-10: C18, C19, C20, K76.8,

Save Data

Identifier

Enter 1 to 5 characters as ID

Email

Your registered email

Other

Email to

Please separate multiple email IDs with comma (,)

Consult Report

Identifier

Enter 1 to 5 characters as ID

Add to MyPath

Select path

New path